Truvestments Capital’s Kymera Therapeutics KYMR Stock Holding History

Truvestments Capital’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.9K	Sell	104 -109	-51%	-$9.37K	﹤0.01%	766
2026 Q1	$17.7K	Sell	213 -61	-22%	-$4.83K	﹤0.01%	669
2025 Q4	$21.3K	Hold	274	–	–	﹤0.01%	579
2025 Q3	$15.5K	Sell	274 -44	-14%	-$1.98K	﹤0.01%	644
2025 Q2	$13.9K	Hold	318	–	–	﹤0.01%	602
2025 Q1	$8.7K	Sell	318 -33	-9%	-$1.2K	﹤0.01%	678
2024 Q4	$14.1K	Buy	351 +54	+18%	+$2.44K	﹤0.01%	545
2024 Q3	$14.1K	Buy	+297	New	+$13.1K	﹤0.01%	533
2024 Q2	–	Sell	-163	Closed	-$6.55K	–	472
2024 Q1	$6.55K	Hold	163	–	–	﹤0.01%	530
2023 Q4	$4.15K	Hold	163	–	–	﹤0.01%	615
2023 Q3	$2.27K	Hold	163	–	–	﹤0.01%	580
2023 Q2	$3.75K	Hold	163	–	–	﹤0.01%	553
2023 Q1	$4.83K	Buy	163 +104	+176%	+$3.35K	﹤0.01%	515
2022 Q4	$1.47K	Hold	59	–	–	﹤0.01%	780
2022 Q3	$1K	Hold	59	–	–	﹤0.01%	591
2022 Q2	$1K	Buy	+59	New	+$1.38K	﹤0.01%	605

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Truvestments Capital's KYMR Position: Q2 2026 in Review

Truvestments Capital reduced its Kymera Therapeutics (KYMR) stake by 51% in Q2 2026, selling an estimated $9.37K and leaving 104 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #766.

Truvestments Capital first reported a position in KYMR in Q2 2022 and has held it in 16 quarters since. The position peaked at $21.3K in Q4 2025. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Truvestments Capital held 104 shares of Kymera Therapeutics worth $11.9K as of Q2 2026.
Truvestments Capital sold 109 Kymera Therapeutics shares in Q2 2026, an estimated $9.37K.
Kymera Therapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #766 holding.
Truvestments Capital first reported a position in Kymera Therapeutics in Q2 2022 and has held it in 16 quarters since.
Truvestments Capital's Kymera Therapeutics position peaked at $21.3K in Q4 2025.
276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.